Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accounts Payables (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Accounts Payables data on record, last reported at $2.9 million in Q4 2025.

  • For Q4 2025, Accounts Payables fell 75.66% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, down 75.66%, while the annual FY2025 figure was $2.9 million, 75.66% down from the prior year.
  • Accounts Payables reached $2.9 million in Q4 2025 per MRVI's latest filing, down from $8.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $718.2 million in Q4 2022 and bottomed at $2.9 million in Q4 2025.
  • Average Accounts Payables over 5 years is $112.0 million, with a median of $9.7 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: soared 8707.95% in 2022, then crashed 99.02% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $8.2 million in 2021, then skyrocketed by 8707.95% to $718.2 million in 2022, then plummeted by 99.02% to $7.1 million in 2023, then skyrocketed by 69.15% to $12.0 million in 2024, then plummeted by 75.66% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $2.9 million in Q4 2025, $8.0 million in Q3 2025, and $11.5 million in Q2 2025.